2025-03-21T16:24:14-05:00 2024-06-30 420714325 RSM US LLP 4 TIMES SQUARE NEW YORK NY 10036 990 2023-07-01 131933825 CANCER RESEARCH FUND OF THE DAMON RUNYON-WALTER WINCHELL FOUNDATION CANC 2124550532 55 BROADWAY 302 NEW YORK NY 10006 DR YUNG LIE PRESIDENT & CHIEF EXECUTIVE OFFICER 2124550532 2025-03-21 1 0 MICHELLE O'NEILL P01372721 2123721072 2025-03-17 2023 2025-03-06 01:10:19Z DR YUNG LIE 55 BROADWAY 302 NEW YORK NY 10006 46908765 0 X WWW.DAMONRUNYON.ORG X 1947 NY ACCELERATING BREAKTHROUGHS BY FUNDING THE MOST INNOVATIVE YOUNG CANCER RESEARCHERS. 39 39 19 205 0 0 9155827 15903193 0 0 6278192 2228565 281656 1427935 15715675 19559693 16621286 20023840 0 0 2742875 2945531 0 0 1904347 1855055 2439313 21219216 25408684 -5503541 -5848991 147680687 160511709 32920972 35205374 114759715 125306335 X TO ACCELERATE BREAKTHROUGHS BY PROVIDING TODAY'S BEST YOUNG SCIENTISTS WITH FUNDING TO PURSUE INNOVATIVE CANCER RESEARCH. THE FOUNDATION'S GOALS ARE TO IDENTIFY AND FUND THE BEST AND BRIGHTEST EARLY-CAREER SCIENTISTS IN CANCER RESEARCH; ENABLE THEM TO TAKE RISKS ON BOLD NEW IDEAS; AND ACCELERATE THE TRANSLATION OF SCIENTIFIC DISCOVERIES INTO NEW WAYS TO PREVENT OR CURE ALL FORMS OF CANCER. ITS INTERNATIONALLY RECOGNIZED AND HIGHLY COMPETITIVE GRANT PROGRAMS ARE DESIGNED TO ACHIEVE THESE GOALS. 1 1 8389965 7568423 0 FELLOWSHIP AWARDS: SUPPORTS THE TRAINING OF THE BRIGHTEST POSTDOCTORAL SCIENTISTS AS THEY EMBARK UPON THEIR RESEARCH CAREERS. THIS FUNDING ENABLES THEM TO BE TRAINED BY ESTABLISHED INVESTIGATORS IN LEADING RESEARCH LABORATORIES ACROSS THE COUNTRY, WHILE INDEPENDENTLY CONDUCTING LEADING-EDGE SCIENCE THAT WILL BRING NEW UNDERSTANDING AND CURES FOR CANCER. 5692872 5134099 0 CLINICAL INVESTIGATOR AWARDS: SUPPORTS EARLY CAREER PHYSICIAN-SCIENTISTS CONDUCTING PATIENT-ORIENTED RESEARCH. THE GOAL OF THIS PROGRAM IS TO INCREASE THE NUMBER OF PHYSICIANS CAPABLE OF MOVING SEAMLESSLY BETWEEN THE LABORATORY AND THE PATIENT'S BEDSIDE IN SEARCH OF BREAKTHROUGH TREATMENTS. 3518952 3191399 0 RACHLEFF INNOVATION AWARDS: SUPPORTS THE NEXT GENERATION OF EXCEPTIONALLY CREATIVE THINKERS WITH "HIGH RISK/HIGH REWARD" IDEAS THAT HAVE THE POTENTIAL TO SIGNIFICANTLY IMPACT OUR UNDERSTANDING OF AND/OR APPROACHES TO THE PREVENTION, DIAGNOSIS OR TREATMENT OF CANCER, BUT LACK SUFFICIENT PRELIMINARY DATA TO OBTAIN TRADITIONAL FUNDING. 1653112 1487839 THE DAMON RUNYON-ST. JUDE PEDIATRIC CANCER RESEARCH FELLOWSHIP AWARD: IN PARTNERSHIP WITH ST. JUDE CHILDREN'S RESEARCH HOSPITAL, THIS AWARD PROVIDES FUNDING TO EARLY CAREER SCIENTISTS CONDUCTING RESEARCH WITH THE POTENTIAL TO SIGNIFICANTLY IMPACT THE PREVENTION, DIAGNOSIS, OR TREATMENT OF ONE OR MORE PEDIATRIC CANCERS. 1060775 961410 PHYSICIAN-SCIENTIST TRAINING AWARDS: SUPPORTS AND ENCOURAGES OUTSTANDING PHYSICIANS TO PURSUE CANCER RESEARCH CAREERS BY PROVIDING THEM WITH THE OPPORTUNITY FOR A PROTECTED RESEARCH TRAINING EXPERIENCE UNDER THE MENTORSHIP OF A HIGHLY QUALIFIED AND GIFTED MENTOR. 925131 846191 QUANTITATIVE BIOLOGY AWARDS: THIS AWARD PROGRAM IS DESIGNED TO ENCOURAGE QUANTITATIVE SCIENTISTS (TRAINED IN FIELDS SUCH AS MATHEMATICS, COMPUTER SCIENCE, PHYSICS, ENGINEERING, AND OTHERS) TO PURSUE RESEARCH CAREERS IN COMPUTATIONAL BIOLOGY UNDER THE JOINT MENTORSHIP OF LEADERS IN BOTH COMPUTATIONAL SCIENCE ("DRY LAB") AND CANCER BIOLOGY ("WET LAB"). BY INVESTING IN THIS AREA, DAMON RUNYON WILL BRING ADDITIONAL ATTENTION TO THE IMPORTANCE OF THESE SPECIALLY TRAINED SCIENTISTS FOR MAKING MEANINGFUL PROGRESS IN CANCER BIOLOGY. 658800 598829 DALE F. FREY AWARDS: AWARDS ARE GIVEN TO THE MOST OUTSTANDING FELLOWS COMPLETING THEIR FELLOWSHIP AWARD, IN THE AMOUNT OF $100,000 EACH, TO ACCELERATE THEIR RESEARCH AND CAREERS. 265153 235650 SPARK SCHOLARS: PROVIDES OUTSTANDING RECENT COLLEGE GRADUATES WITH THE POTENTIAL TO BECOME SCIENTIFIC LEADERS WITH A FINANCIAL STIPEND, INTENSIVE LABORATORY TRAINING, A NETWORK OF MENTORS AND PEERS, AND OTHER RESOURCES TO SUPPORT THEIR NEXT CAREER STEPS. 4562971 4129919 22164760 1 1 0 0 0 0 0 0 0 1 1 1 0 1 1 1 1 0 0 0 1 0 1 0 1 0 0 0 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 53 0 1 19 1 0 0 0 0 0 1 1 0 0 0 0 0 0 X 39 39 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AK AL AR AZ CA CO CT FL GA HI IL KS KY MA MD ME MI MS MN MO NC NJ NH NM NY OH OK OR PA RI SC TN UT VA WA WI WV X X TRAVIS CAREY 2124550532 55 BROADWAY 302 NEW YORK NY 10006 X CARLOS L ARTEAGA MD DIRECTOR 1.00 0.00 X 0 0 0 DAVID M BEIRNE VICE CHAIR 1.00 0.00 X 0 0 0 STEVEN J BURAKOFF MD DIRECTOR 1.00 0.00 X 0 0 0 MELISSA L COHN DIRECTOR (AS OF 10/30/23) 1.00 0.00 X 0 0 0 ROBYN COLES DIRECTOR 1.00 0.00 X 0 0 0 GARY E ERLBAUM DIRECTOR 1.00 0.00 X 0 0 0 BUCK FRENCH DIRECTOR 1.00 0.00 X 0 0 0 ELAINE V FUCHS PHD DIRECTOR 1.00 0.00 X 0 0 0 LEVI A GARRAWAY MD PHD DIRECTOR 1.00 0.00 X 0 0 0 RICHARD B GAYNOR MD DIRECTOR 1.00 0.00 X 0 0 0 ERICA EVANS GIOFFRE DIRECTOR (AS OF 03/06/24) 1.00 0.00 X 0 0 0 TODD R GOLUB MD DIRECTOR 1.00 0.00 X 0 0 0 DAVID A GORDON PHD DIRECTOR (AS OF 10/30/23) 1.00 0.00 X 0 0 0 SCOTT GREENSTEIN DIRECTOR 1.00 0.00 X 0 0 0 STEVE HAYDEN DIRECTOR (THRU 10/23/2023) 1.00 0.00 X 0 0 0 MORANA JOVAN-EMBIRICOS PHD DIRECTOR 1.00 0.00 X 0 0 0 STEVEN A KANDARIAN DIRECTOR 1.00 0.00 X 0 0 0 NOAH KNAUF DIRECTOR 1.00 0.00 X 0 0 0 GABRIELLE LAYTON PHD DIRECTOR 1.00 0.00 X 0 0 0 GERALD M MARAHALL DIRECTOR (AS OF 10/30/23) 1.00 0.00 X 0 0 0 RICHARD W MEIER DIRECTOR 1.00 0.00 X 0 0 0 JOHN H MYERS DIRECTOR 1.00 0.00 X 0 0 0 RICHARD J O'REILLY MD DIRECTOR 1.00 0.00 X 0 0 0 JOSEPH PEARLBERG MD PHD DIRECTOR 1.00 0.00 X 0 0 0 LORI J PIERCE MD DIRECTOR 1.00 0.00 X 0 0 0 ANDREW S RACHLEFF DIRECTOR 1.00 0.00 X 0 0 0 ADAM R SCHWARTZ DIRECTOR (AS OF 10/30/23) 1.00 0.00 X 0 0 0 MICHAEL V SEIDEN MD PHD DIRECTOR 1.00 0.00 X 0 0 0 KAREN D SEITZ DIRECTOR 1.00 0.00 X 0 0 0 NANCY SIMONIAN MD DIRECTOR 1.00 0.00 X 0 0 0 AMOOLYA SINGH PHD DIRECTOR (AS OF 03/06/24) 1.00 0.00 X 0 0 0 CYNTHIA SULZBERGER DIRECTOR 1.00 0.00 X 0 0 0 JUDY SWANSON DIRECTOR 1.00 0.00 X 0 0 0 PETER VAN CAMP DIRECTOR 1.00 0.00 X 0 0 0 JAMES WELLS PHD DIRECTOR 1.00 0.00 X 0 0 0 DEBORAH J COLEMAN CHAIR 1.00 0.00 X X 0 0 0 WILLIAM G KAELIN JR MD VICE CHAIR, SCIENTIFIC PROGRAMS 1.00 0.00 X X 0 0 0 MICHAEL L GORDON VICE CHAIR, BOARD DEVELOPMENT 1.00 0.00 X X 0 0 0 DAVID G MARSHALL VICE CHAIR, INVESTMENTS & TREASURER 1.00 0.00 X X 0 0 0 SANFORD W MORHOUSE ESQ VICE CHAIR, AUDIT & SECRETARY 1.00 0.00 X X 0 0 0 YUNG S LIE PHD PRESIDENT & CEO 40.00 0.00 X 533687 0 65712 CLARE CAHILL CHIEF ADMINISTRATIVE OFFICER 40.00 0.00 X 245416 0 40690 KIMBERLY KUBERT DIRECTOR OF SPECIAL EVENTS 40.00 0.00 X 205635 0 47338 MEGHAN MCCURDY DIR. OF COMMUNICATIONS & MARKETING 40.00 0.00 X 150319 0 37914 JOHN SPAIN DIRECTOR OF DEVELOPMENT OPERATIONS 40.00 0.00 X 134185 0 28861 ELYSE HOFFMANN DIRECTOR OF STRATEGIC PARTNERSHIP 40.00 0.00 X 152327 0 36942 1421569 0 257457 7 0 1 0 CRAFT & COMMERCE 714 N HYE AVENUE ORLANDO FL 32803 MARKETING 196500 JP MORGAN 270 PARK AVENUE NEW YORK NY 10017 INVESTMENT ADVISORY 139586 BOUCHEZPAGE 55 5TH AVENUE NEW YORK NY 10003 PRODUCTION MANAGEMENT 125000 ALPINE ASCENT INTERNATIONAL 109 WEST MERCER STREET SEATTLE WA 98119 FUNDRAISING EVENT MANAGEMENT 103200 RSM US LLP 151 WEST 42ND STREET FLOORS 18-20 NEW YORK NY 10036 ACCOUNTING SERVICES 102975 6 1181987 14721206 802524 15903193 3360399 3360399 1263499 1263499 25710326 26842160 -1131834 -1131834 -1131834 315790 1181987 506912 -191122 -191122 TRUST INCOME 525990 334019 334019 MISCELLANEOUS 900099 21539 21539 355558 19559693 0 0 3656500 19923840 19923840 100000 100000 550016 357510 55002 137504 1792314 602695 382729 806890 155776 63858 29111 62807 303511 124420 56720 122371 143914 58996 26894 58024 15873 6505 2966 6402 197851 81106 36974 79771 139586 139586 314390 128882 58753 126755 178153 56423 121730 54884 22499 10256 22129 103387 42382 19321 41684 358820 147093 67056 144671 117544 117544 100118 100118 26843 11004 5016 10823 36311 14885 6786 14640 BAD DEBT EXPENSE 371800 371800 ADVISORY COMMITTEE SERV 347852 347852 BOARD MEETING COSTS 22859 9371 4272 9216 AWARD RELATED 14449 5924 2699 5826 38593 15820 7213 15560 25408684 22164760 1339577 1904347 147903 148992 18736822 16595615 5982502 7056004 296671 244198 179381 167213 807101 618632 135325 188469 37970856 44513296 75546263 82691491 8684964 8906431 147680687 160511709 385596 428342 29506447 32112667 937917 897211 2091012 1767154 32920972 35205374 X 97419092 106512416 17340623 18793919 114759715 125306335 147680687 160511709 X -5848991 15911289 484322 X 0 1 X 1 0 X 15679052 15008268 8036836 9155827 15903193 63783176 15679052 15008268 8036836 9155827 15903193 63783176 7562359 56220817 3423842 2945775 3424747 3076164 4957917 17828445 415451 58174 364423 324597 337329 1499974 83111595 0.67640 0.60110 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: SPECIAL EVENT INCOME MISCELLANEOUS INCOME RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 126338483 3729706 18139854 7500000 139586 140568457 120646027 2779866 14412590 11500000 126338483 142590768 2202136 -17472677 6500000 174200 120646027 115139591 6398765 33243829 11000000 676757 514660 142590768 133032433 2072032 4535126 19476518 2085716 2937766 115139591 0.91930 0.00190 0.07880 0 0 376804 272100 104704 191681 107916 83765 238616 238616 0 188469 LIMITED PARTNERSHIPS & DEBT SECURITIES 10294573 F FIDELITY INTL INDX-INST PRM 8271103 F FIDELITY 500 INDEX FUND 52861307 F VANGUARD TTL INTL BND-ADM 11264508 F 82691491 AMOUNT HELD IN TRUST BY OTHERS 7467863 OPERATING LEASE RIGHT-OF-USE ASSET 1438568 8906431 OPERATING LEASE LIABILITY 1767154 1767154 X 36561710 15911289 366000 484322 16761611 19800099 139586 -379992 -240406 19559693 26015090 366000 379992 745992 25269098 139586 139586 25408684 PART V, LINE 4: ENDOWMENT ASSETS ARE REPRESENTED BY AVAILABLE FUNDS ALLOCATED BY THE FOUNDATION FOR LONG-TERM INVESTMENT, AND FUNDS RECEIVED FROM DONORS FOR FUNDING OF SCIENTIFIC AWARDS THAT ARE INCLUDED IN NET ASSETS WITH DONOR RESTRICTIONS. THE INCOME GENERATED BY THESE FUNDS CAN BE USED FOR UNRESTRICTED PURPOSES. PART X, LINE 2: THE FOUNDATION IS INCORPORATED AS A NEW YORK NONPROFIT CORPORATION AND HAS BEEN RECOGNIZED BY THE INTERNAL REVENUE SERVICE (IRS) AS EXEMPT FROM FEDERAL INCOME TAXES UNDER INTERNAL REVENUE CODE (IRC) SECTION 501(A) AS AN ORGANIZATION DESCRIBED IN IRC SECTION 501(C)(3), QUALIFIES FOR THE CHARITABLE CONTRIBUTION DEDUCTION UNDER IRC SECTIONS 107(B)(1)(A)(VI) AND (VIII), AND HAD BEEN DETERMINED NOT TO BE A PRIVATE FOUNDATION UNDER IRC SECTIONS 509(A)(1) AND (3). THE FOUNDATION IS ANNUALLY REQUIRED TO FILE A RETURN OF ORGANIZATION EXEMPT FROM INCOME TAX (FORM 990) WITH THE IRS. IN ADDITION, THE FOUNDATION IS SUBJECT TO INCOME TAX ON NET INCOME THAT IS DERIVED FROM BUSINESS ACTIVITIES THAT ARE UNRELATED TO ITS EXEMPT PURPOSES (UBI). FOR THE YEARS ENDED JUNE 30, 2024 AND 2023, THE FOUNDATION DID NOT INCUR ANY UBIT, AND HAS NOT FILED AN EXEMPT ORGANIZATION BUSINESS INCOME TAX RETURN (FORM 990-T) WITH THE IRS. PART XI, LINE 2D - OTHER ADJUSTMENTS: CHANGE IN VALUE OF CHARITABLE REMAINDER TRUSTS 129,957. CHANGE IN VALUE OF PERPETUAL TRUSTS 354,365. PART XI, LINE 4B - OTHER ADJUSTMENTS: SPECIAL EVENTS EXPENSES NETTED AGAINST SPECIAL EVENTS INCOME -379,992. PART XII, LINE 2D - OTHER ADJUSTMENTS: SPECIAL EVENTS EXPENSES NETTED AGAINST SPECIAL EVENTS INCOME 379,992. 1 CENTRAL AMERICA AND THE CARIBBEAN INVESTMENTS 10294148 EAST ASIA AND THE PACIFIC 0 0 GRANTMAKING 100000 0 0 0 0 0 0 10394148 0 10394148 DALE FREY AWARD EAST ASIA AND THE PACIFIC 1 100000 WIRE TRANSFER 0 0 0 0 1 0 PART I, LINE 2: GRANTS TO FELLOWS AT FOREIGN RESEARCH INSTITUTIONS MUST SUBMIT THE SAME RESEARCH AND REPORTS AS FELLOWS WORKING IN THE UNITED STATES. THE PROGRAM TEAM MONITORS THEIR RESEARCH REPORTS AND FINDINGS ANNUALLY. DAMON RUNYON BREAKFAST 1041504 1014004 27500 0 0 39171 13057 22143 11459 THEATRE BOX OFFICE 205986 112920 93066 0 0 0 0 116999 9921 7 250287 55063 195224 0 14505 176733 36017 30082 36825 1497777 1181987 315790 14505 215904 49074 169224 58205 506912 -191122 1 DAMON RUNYON FELLOWSHIP AWARDS 91 7568423 DAMON RUNYON CLINICAL INVESTIGATOR AWARDS & CONTINUATION GRANTS 10 5134099 DAMON RUNYON RACHLEFF INNOVATION AWARDS 8 3191399 DALE FREY AWARDS 5 498829 PHYSICIAN SCIENTIST AWARDS 4 961410 QUANTITATIVE BIOLOGY AWARDS 4 846191 ST. JUDE PEDIATRIC CANCER AWARD 5 1487839 SPARK SCHOLAR AWARDS 4 235650 PART I, LINE 2: THE ORGANIZATION REQUIRES ANNUAL REPORTS OF PROGRESS BY THE AWARDEES AS WELL AS AN ACCOUNTING OF THE AWARD EXPENDITURES. X X X X X 0 0 0 0 0 0 0 1 0 YUNG S LIE PHD PRESIDENT & CEO 483687 0 50000 0 0 0 33000 0 32712 0 599399 0 0 0 CLARE CAHILL CHIEF ADMINISTRATIVE OFFICER 227916 0 17500 0 0 0 22352 0 18338 0 286106 0 0 0 KIMBERLY KUBERT DIRECTOR OF SPECIAL EVENTS 188135 0 17500 0 0 0 18450 0 28888 0 252973 0 0 0 ELYSE HOFFMANN DIRECTOR OF STRATEGIC PARTNERSHIP 152327 0 0 0 0 0 0 0 36942 0 189269 0 0 0 MEGHAN MCCURDY DIR. OF COMMUNICATIONS & MARKETING 150319 0 0 0 0 0 7546 0 30368 0 188233 0 0 0 JOHN SPAIN DIRECTOR OF DEVELOPMENT OPERATIONS 134185 0 0 0 0 0 13159 0 15702 0 163046 0 0 0 PART I, LINE 7 THE FOLLOWING INDIVIDUALS, LISTED ON PART VII, RECEIVED A NON-FIXED PAYMENT IN THE FORM OF A BONUS DURING THE 2023 YEAR: YUNG LIE - $50,000 CLARE CAHILL - $17,500 KIMBERLY KUBERT - $17,500 X 11 802524 FMV 0 0 0 0 PART I, COLUMN (B): THE NUMBER OF CONTRIBUTIONS SHOWN ABOVE REPRESENTS THE NUMBER OF DONORS OF PUBLICLY TRADED STOCK DURING THE YEAR. FORM 990, PART III, LINE 2 THE FOUNDATION HAS LAUNCHED A NEW PEDIATRIC CANCER RESEARCH AWARD IN COLLABORATION WITH ST. JUDE CHILDREN'S RESEARCH HOSPITAL TO FUND FELLOWS SPECIALIZING IN BREAKTHROUGHS IN PEDIATRIC CANCER. ADDITIONALLY, THE FOUNDATION HAS INTRODUCED THE DAMON RUNYON SCHOLARS PROGRAM FOR ADVANCING RESEARCH AND KNOWLEDGE (SPARK) AWARD. FORM 990, PART III, LINE 3 THE THE DAMON RUNYON-SOHN PEDIATRIC CANCER FELLOWSHIP AWARD HAS BEEN REPLACED BY THE ST. JUDE PEDIATRIC CANCER RESEARCH FELLOWSHIP AWARD. FORM 990, PART VI, SECTION A, LINE 2 DAVID MARSHALL AND GERALD MARSHALL HAVE A FAMILY RELATIONSHIP. MICHAEL GORDON AND DAVID GORDON HAVE A FAMILY RELATIONSHIP. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS REVIEWED FIRST BY THE PRESIDENT & CEO AND THE FINANCE CONSULTANT. IT IS THEN PRESENTED TO THE AUDIT COMMITTEE FOR REVIEW AND APPROVAL. IT IS SUBSEQUENTLY PROVIDED TO THE BOARD OF DIRECTORS FOR INFORMATION BEFORE IT IS FILED WITH THE IRS AND IS THEN REVIEWED AT THE NEXT BOARD MEETING. FORM 990, PART VI, SECTION B, LINE 12C THE CONFLICT OF INTEREST POLICY IS PROVIDED TO ALL MEMBERS OF THE BOARD OF DIRECTORS, AS WELL AS ALL MEMBERS OF THE STAFF AND THOSE SERVING ON AWARD COMMITTEES. ON AN ANNUAL BASIS, BOARD MEMBERS AND SENIOR STAFF ARE REQUIRED TO SIGN THE CONFLICT OF INTEREST QUESTIONNAIRE, NOTING ANY POTENTIAL CONFLICTS OF INTEREST. STAFF MEMBERS AND AWARD COMMITTEE MEMBERS SIGN THIS QUESTIONNAIRE PRIOR TO COMMENCING EMPLOYMENT OR SERVING ON THE COMMITTEE, RESPECTIVELY. IT SHALL BE THE CONTINUING DUTY OF EACH PERSON COMPLETING THE QUESTIONNAIRE TO ADVISE THE BOARD OF DIRECTORS, THROUGH THE SECRETARY, PROMPTLY OF ANY CIRCUMSTANCES THAT WOULD ALTER THE ANSWER TO ANY QUESTION ON HIS OR HER COMPLETED QUESTIONNAIRE. POTENTIAL CONFLICTS OF INTEREST ARE THEN REVIEWED BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS. ANY INDIVIDUAL DETERMINED TO HAVE A CONFLICT OF INTEREST, OR APPEARANCE OF A CONFLICT OF INTEREST, WITH RESPECT TO ANY MATTER, SHALL NOT VOTE OR PARTICIPATE IN OR BE PRESENT AT ANY DELIBERATIONS OR USE HIS OR HER PERSONAL INFLUENCE IN SUCH MATTER. THE RECUSAL OF THE INDIVIDUAL FROM PARTICIPATION SHALL BE RECORDED IN THE MINUTES OF THE MEETING AT WHICH SUCH MATTER IS ACTED UPON. FORM 990, PART VI, SECTION B, LINE 15 COMPENSATION OF THE PRESIDENT & CHIEF EXECUTIVE OFFICER AND SENIOR STAFF IS DETERMINED ANNUALLY AFTER REVIEW OF THEIR PERFORMANCE BY THE CHAIRMAN OF THE BOARD. THE CHAIRMAN OF THE BOARD IS SUPPORTED IN THIS PROCESS BY A COMPENSATION COMMITTEE WHICH REVIEWS THE PERFORMANCE REVIEWS AND COMPARABILITY DATA. THE BOARD CHAIR THEN PRESENTS THE REVIEW AND RECOMMENDATION ON COMPENSATION TO THE EXECUTIVE COMMITTEE OF THE BOARD FOR REVIEW AND APPROVAL. IT IS THEN REVIEWED AND APPROVED BY THE BOARD OF DIRECTORS IN EXECUTIVE SESSION AT ITS NEXT MEETING. IN SEPTEMBER OF 2022, AN OUTSIDE COMPENSATION CONSULTANT WAS ENGAGED TO CONDUCT A COMPENSATION STUDY, WHICH INCLUDED A FORMAL REVIEW OF KEY POSITIONS. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION'S GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS ARE AVAILABLE TO THE PUBLIC UPON REQUEST FOR THE SAME PERIOD OF DISCLOSURE AS SET FORTH IN SECTION 6104(D). THE FINANCIAL STATEMENTS ARE ALSO POSTED ON THE ORGANIZATION'S WEBSITE. FORM 990, PART VII THE ORGANIZATION, IN A FULL TRANSPARENCY POSTURE TO REPORTING, IS REPORTING ALL BENEFITS IN FULL IN PART VII, COLUMN F AND NOT APPLYING THE $10,000 PER ITEM EXCEPTION FOR CERTAIN BENEFITS. FORM 990, PART XI, LINE 9: CHANGE IN VALUE OF CHARITABLE REMAINDER TRUSTS 129,957. CHANGE IN VALUE OF PERPETUAL TRUSTS 354,365.